RecruitingNCT03280394

Liquid Biopsy in Mature B-cell Tumors

Prospective, Observational, Multi-centred, Non-interventional Research Project on Plasma Cell Free DNA Genotyping as a Tool to Inform Mature B-cell Tumor Management

Sponsor

Oncology Institute of Southern Switzerland

Enrollment

444 participants

Start Date

Sep 1, 2017

Study Type

OBSERVATIONAL

Conditions

Mature B-Cell Neoplasm

Summary

The study aims at assessing whether cell free DNA genotyping can improve the accuracy of early prediction of cure in mature B-cell tumor patients and whether it represents an accessible source of tumor DNA for the sensitive identification of genetic biomarkers that refine the diagnostic workup, stratify prognosis and identify the emergence of drug-resistance mutations during treatment.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether a "liquid biopsy" — a blood test that looks for pieces of tumor DNA or cancer cells circulating in the blood — can be used to diagnose, track, and monitor a group of blood cancers called mature B-cell tumors (types of lymphoma and leukemia that affect B immune cells). **You may be eligible if...** - You are 18 years or older - You have a confirmed diagnosis of a mature B-cell tumor (a type of blood cancer, such as certain lymphomas or chronic lymphocytic leukemia) according to standard criteria - You are willing to follow the scheduled study procedures and sign a consent form **You may NOT be eligible if...** - There are no additional exclusion criteria listed beyond the basic inclusion requirements Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTLiquid Biopsy

Assessing whether plasma cell free DNA improves the accuracy of early prediction of cure in mature B-cell tumor patients and whether it represents an accessible source of tumor DNA for the sensitive identification of genetic biomarkers that, at disease presentation, refine the diagnostic workup in mature B-cell tumor patients and, upon treatment, early identify the emergence of resistance mutations.

Locations(1)

Institute of Oncology Research

Bellinzona, Canton Ticino, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03280394

Related Trials

Study of SGR-1505 in Mature B-Cell Neoplasms

NCT0554401936 locations